Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.45 |
| ▸ | NPY1R | P25929 | 9/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.45 |
| ▸ | NPY2R | P49146 | 5/20 | 0.45 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4082489 | 0.90 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL4082725 | 0.89 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL4096309 | 0.89 | NPY4R (0.42) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL4082548 | 0.89 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL4089663 | 0.89 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31415951 | 0.85 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL4086556 | 0.83 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29995622 | 0.82 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL4096369 | 0.82 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL9294796 | 0.82 | VIPR2 (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
| EP-2007794-A1 | LYSOBACTIN AMIDES | AiCuris GmbH & Co. KG (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007118691-A1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | NPY4R 1014/4885NPY1R 2090/4885NPY5R 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.